Literature DB >> 15794385

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.

Robert J Fox1, Elizabeth Fisher, Jean Tkach, Jar-Chi Lee, Jeffrey A Cohen, Richard A Rudick.   

Abstract

BACKGROUND: The short-term effect of corticosteroids on MRI measures of multiple sclerosis (MS) is not well understood and may have a significant impact when using these quantitative measures to evaluate disease activity and changes following other therapeutic interventions.
OBJECTIVE: To determine the impact of a course of intravenous methylprednisolone (IVMP) on quantitative measures of disease activity and tissue injury in MS patients.
METHODS: We prospectively measured brain parenchymal fraction (BPF), magnetization transfer ratio (MTR, lesional and whole brain), and lesion volumes on nine weekly brain MRI studies in ten MS patients receiving a course of IVMP. A group of nine MS patients not receiving IVMP served as controls.
RESULTS: In comparison to untreated controls, BPF declined over the eight weeks following IVMP treatment (P <0.02). BPF decline was most prominent in patients with secondary progressive MS (SPMS, P <0.03), and was not seen in relapsing-remitting (RR) MS patients. Short-term change in BPF correlated with baseline BPF (r =0.62, P =0.05) and short-term change in lesional MTR (r = -0.55, P =0.03), but not with change in enhancing lesion volume. Short-term change in lesional MTR inversely correlated with baseline lesional and whole brain MTR (r = -0.79, P =0.04 for both). There was no significant difference between treated and control patients in measures of MTR or T2, T1 or enhancing lesion volumes.
CONCLUSIONS: Patients with SPMS showed a greater decline in BPF following IVMP than RRMS patients. A correlation between changes in BPF and MTR suggest that these changes are secondary to altered water content within MS lesions. Differential response to a standardized therapeutic intervention in RRMS and SPMS suggests that responses to therapy may differ due to a fundamental pathologic difference between early and late stage MS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794385     DOI: 10.1191/1352458505ms1142oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

Review 1.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

2.  Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques.

Authors:  F Durand-Dubief; B Belaroussi; J P Armspach; M Dufour; S Roggerone; S Vukusic; S Hannoun; D Sappey-Marinier; C Confavreux; F Cotton
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

3.  Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.

Authors:  M Varosanec; T Uher; D Horakova; J Hagemeier; N Bergsland; M Tyblova; Z Seidl; M Vaneckova; J Krasensky; M G Dwyer; E Havrdova; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2015-06-25       Impact factor: 3.825

4.  Monophasic demyelination reduces brain growth in children.

Authors:  Bérengère Aubert-Broche; Katrin Weier; Giulia Longoni; Vladimir S Fonov; Amit Bar-Or; Ruth Ann Marrie; E Ann Yeh; Sridar Narayanan; Douglas L Arnold; Leonard H Verhey; Brenda Banwell; D Louis Collins
Journal:  Neurology       Date:  2017-04-05       Impact factor: 9.910

5.  Development and aging of superficial white matter myelin from young adulthood to old age: Mapping by vertex-based surface statistics (VBSS).

Authors:  Minjie Wu; Anand Kumar; Shaolin Yang
Journal:  Hum Brain Mapp       Date:  2016-03-09       Impact factor: 5.038

6.  Management of acute exacerbations in multiple sclerosis.

Authors:  Daniel Ontaneda; Alex D Rae-Grant
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

Review 7.  Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve.

Authors:  Massimo Filippi; Maria A Rocca
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

8.  Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling.

Authors:  Blake C Jones; Govind Nair; Colin D Shea; Ciprian M Crainiceanu; Irene C M Cortese; Daniel S Reich
Journal:  Neuroimage Clin       Date:  2013-08-13       Impact factor: 4.881

9.  MRI correlates of disability progression in patients with CIS over 48 months.

Authors:  Tomas Uher; Dana Horakova; Niels Bergsland; Michaela Tyblova; Deepa P Ramasamy; Zdenek Seidl; Manuela Vaneckova; Jan Krasensky; Eva Havrdova; Robert Zivadinov
Journal:  Neuroimage Clin       Date:  2014-09-28       Impact factor: 4.881

10.  Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.

Authors:  Shannon Kolind; Arshia Seddigh; Anna Combes; Bretta Russell-Schulz; Roger Tam; Vignan Yogendrakumar; Sean Deoni; Naomi A Sibtain; Anthony Traboulsee; Steven C R Williams; Gareth J Barker; Peter A Brex
Journal:  Neuroimage Clin       Date:  2015-10-03       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.